Advertisements were blocked or nothing was served
We understand that advertisements are annoying, and fully support the usage with ads disabled. please support us in any way you can.
Mandatory update in 12.2 days @ block 2671700
The Gridcoin Research wallet v5.4.0.0 is released, which is a mandatory update.
On block 2671700, in about 12.2 days older wallets will no longer be able to connect to the network.
Upgrade to the latest wallet by downloading it from the GitHub repository.
The following news story was loaded from an external source. The story is not related to this site.

COVID-19 vaccine with IPD nanoparticles wins full approval abroad

Tag: boinc:rosetta@home
Published 2022-07-06 20:27:59




The IPD is excited to announce it's first designed protein medicine with full approval abroad.

Congrats and thank you to all Rosetta@home contributors! The computing you have provided has greatly aided in de novo protein design challenges such as vaccine development leading to breakthroughs like this.

For more information you can visit the IPD vaccine news post.

A video is also available here.


From the IPD news site:

• Clinical testing found the vaccine outperforms Oxford/AstraZeneca’s

• The protein-based vaccine, now called SKYCovione, does not require deep freezing

• University of Washington to waive royalty fees for the duration of the pandemic

• South Korea to purchase 10 million doses for domestic use

A vaccine for COVID-19 developed at the University of Washington School of Medicine has been approved by the Korean Ministry of Food and Drug Safety for use in individuals 18 years of age and older. The vaccine, now known as SKYCovione, was found to be more effective than the Oxford/AstraZeneca vaccine sold under the brand names Covishield and Vaxzevria.

SK bioscience, the company leading the SKYCovione’s clinical development abroad, is now seeking approval for its use in the United Kingdom and beyond. If approved by the World Health Organization, the vaccine will be made available through COVAX, an international effort to equitably distribute COVID-19 vaccines around the world. In addition, the South Korean government has agreed to purchase 10 million doses for domestic use.

The Seattle scientists behind the new vaccine sought to create a ‘second-generation’ COVID-19 vaccine that is safe, effective at low doses, simple to manufacture, and stable without deep freezing. These attributes could enable vaccination at a global scale by reaching people in areas where medical, transportation, and storage resources are limited.

“We know more than two billion people worldwide have not received a single dose of vaccine,” said David Veesler, associate professor of biochemistry at UW School of Medicine and co-developer of the vaccine. “If our vaccine is distributed through COVAX, it will allow it to reach people who need access.”

The University of Washington is licensing the vaccine technology royalty-free for the duration of the pandemic.

Congrats and thank you again to all R@h contributors!


Read the story on the source
Disclaimer
All content provided herein our website, hyperlinked sites, associated applications, forums, blogs, social media accounts and other platforms is for your general information only, procured from third party sources. We make no warranties of any kind in relation to our content, including but not limited to accuracy and updatedness. No part of the content that we provide constitutes financial advice, legal advice or any other form of advice meant for your specific reliance for any purpose. Any use or reliance on our content is solely at your own risk and discretion. Sources are Berkeley Open Infrastructure for Network Computing or Gridcoin. Read on what and how you can remove yourself
Rendered in 0.0123s with 3 backend requests in 0.0073s
Memory Usage: 421.99 kb (1 mb)
App version: 111493f@refs/heads/master
Updated on: 2022-08-02 20:43:25 +0200